118 related articles for article (PubMed ID: 9741671)
1. Photodecontamination of blood components: advantages and drawbacks.
Santus R; Grellier P; Schrével J; Mazière JC; Stoltz JF
Clin Hemorheol Microcirc; 1998 Jul; 18(4):299-308. PubMed ID: 9741671
[TBL] [Abstract][Full Text] [Related]
2. Virus inactivation in blood components by photoactive phenothiazine dyes.
Wagner SJ
Transfus Med Rev; 2002 Jan; 16(1):61-6. PubMed ID: 11788930
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.
Trannoy LL; Terpstra FG; de Korte D; Lagerberg JW; Verhoeven AJ; Brand A; van Engelenburg FA
Vox Sang; 2006 Aug; 91(2):111-8. PubMed ID: 16907871
[TBL] [Abstract][Full Text] [Related]
4. Chalcogenoxanthylium photosensitizers for the photodynamic purging of blood-borne viral and bacterial pathogens.
Wagner SJ; Skripchenko A; Donnelly DJ; Ramaswamy K; Detty MR
Bioorg Med Chem; 2005 Nov; 13(21):5927-35. PubMed ID: 16140537
[TBL] [Abstract][Full Text] [Related]
5. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
Blajchman MA
Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
[TBL] [Abstract][Full Text] [Related]
6. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
7. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficiency and the specificity of DNA-bound and free cationic porphyrin in photodynamic virus inactivation.
Zupán K; Egyeki M; Tóth K; Fekete A; Herényi L; Módos K; Csík G
J Photochem Photobiol B; 2008 Feb; 90(2):105-12. PubMed ID: 18222092
[TBL] [Abstract][Full Text] [Related]
9. The application of photosensitisers to tropical pathogens in the blood supply.
Wainwright M; Baptista MS
Photodiagnosis Photodyn Ther; 2011 Sep; 8(3):240-8. PubMed ID: 21864797
[TBL] [Abstract][Full Text] [Related]
10. Pathogen inactivation technology: cleansing the blood supply.
Klein HG
J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
[TBL] [Abstract][Full Text] [Related]
11. Dithiaporphyrin derivatives as photosensitizers in membranes and cells.
Minnes R; Weitman H; You Y; Detty MR; Ehrenberg B
J Phys Chem B; 2008 Mar; 112(10):3268-76. PubMed ID: 18278897
[TBL] [Abstract][Full Text] [Related]
12. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
13. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties.
Skripchenko A; Wagner SJ; Thompson-Montgomery D; Awatefe H
Transfusion; 2006 Feb; 46(2):213-9. PubMed ID: 16441597
[TBL] [Abstract][Full Text] [Related]
14. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
15. In vitro demonstration of the heavy-atom effect for photodynamic therapy.
Gorman A; Killoran J; O'Shea C; Kenna T; Gallagher WM; O'Shea DF
J Am Chem Soc; 2004 Sep; 126(34):10619-31. PubMed ID: 15327320
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.
Isola H; Kientz D; Aleil B; Laeuffer P; Weil J; Wiesel ML; Laforêt M; Lin L; Mayaudon V; Cazenave JP
Vox Sang; 2006 Feb; 90(2):128-30. PubMed ID: 16430671
[TBL] [Abstract][Full Text] [Related]
17. Pathogen inactivation: a new paradigm for blood safety.
McCullough J
Transfusion; 2007 Dec; 47(12):2180-4. PubMed ID: 18036073
[No Abstract] [Full Text] [Related]
18. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
19. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
20. Quality of methylene-blue-treated fresh-frozen plasma stored up to 27 months.
Moog R; Reichenberg S; Hoburg A; Müller N
Transfusion; 2010 Feb; 50(2):516-8. PubMed ID: 20233360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
